APLI.F Stock Overview
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Appili Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.028 |
| 52 Week High | CA$0.075 |
| 52 Week Low | CA$0.016 |
| Beta | 1.15 |
| 1 Month Change | -17.16% |
| 3 Month Change | 35.27% |
| 1 Year Change | -8.79% |
| 3 Year Change | -97.17% |
| 5 Year Change | n/a |
| Change since IPO | -97.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| APLI.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.1% | 1.1% | 0.6% |
| 1Y | -8.8% | 9.4% | 23.9% |
Return vs Industry: APLI.F underperformed the US Pharmaceuticals industry which returned 9.4% over the past year.
Return vs Market: APLI.F underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| APLI.F volatility | |
|---|---|
| APLI.F Average Weekly Movement | 35.2% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: APLI.F's share price has been volatile over the past 3 months.
Volatility Over Time: APLI.F's weekly volatility has increased from 26% to 35% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 9 | Don Cilla | www.appilitherapeutics.com |
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
Appili Therapeutics Inc. Fundamentals Summary
| APLI.F fundamental statistics | |
|---|---|
| Market cap | US$3.10m |
| Earnings (TTM) | -US$3.90m |
| Revenue (TTM) | US$840.57k |
3.7x
P/S Ratio-0.8x
P/E RatioIs APLI.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APLI.F income statement (TTM) | |
|---|---|
| Revenue | CA$1.15m |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$1.15m |
| Other Expenses | CA$6.49m |
| Earnings | -CA$5.34m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.044 |
| Gross Margin | 100.00% |
| Net Profit Margin | -464.23% |
| Debt/Equity Ratio | -81.5% |
How did APLI.F perform over the long term?
See historical performance and comparison